NCI-H929/iRFP cells are derived from the human B lymphocyte NCI-H929 cell line by stably integration of a constitutive miRFP670 stably expression construct. NCI-H929 cells stably express B cell maturation antigen (BCMA)-a novel treatment target for multiple myeloma (MM), and have been widely used in cancer research and drug development. NCI-H929/iRFP cells stably stably express miRFP670, can be used for in vitro assays and in vivo imaging.
